Novartis Share Price Today

Novartis to unveil remibrutinib Phase III data at MSToronto2026

Novartis to present late-breaking Phase III REMODEL-1/-2 data for remibrutinib at MSToronto2026. Total of 46 abstracts from the multiple sclerosis portfolio will be showcased at the conference. New evidence for Kesimpta in pediatric MS and breastfeeding safety to be presented. Investor call scheduled to discuss remibrutinib data and potential market impact.

Evonile Pharma board to consider rights issue on October 8

Evonile Pharma Limited schedules board meeting for October 8, 2026. Board to consider rights issue of equity shares with face value ₹5. Trading window closed from October 1 to November 5, 2026. Fund raising subject to regulatory and statutory approvals.

Novartis India declares voting results of 78th AGM, approves name change

All 16 resolutions passed at Novartis India's 78th AGM held on September 24, 2026. Name change to Evonile Pharma Limited approved with 99.99% votes in favor. ESOP 2026 scheme ratified with 99.05% overall support despite institutional dissent. Seven director appointments regularized, including Ramesh Ramadurai as Independent Director.

Manhattan judge rules for Novartis in Entresto patent dispute

A federal judge in Manhattan ruled in favor of Novartis. The ruling dismissed allegations of patent misuse. The case concerned exclusivity on the heart-failure drug Entresto. The decision was issued on Wednesday.

Novartis India to participate in Nuvama CEO Forum on Sep 28

Novartis India Limited will attend the Nuvama Emerging India CEO Forum on September 28, 2026. Meetings will be held in person in Mumbai, featuring one-on-one and group formats. The company confirmed that no unpublished price sensitive information (UPSI) will be disclosed. The event participation complies with Regulation 30 of SEBI (LODR) Regulations, 2015.

Novartis secures positive CHMP opinion for Cosentyx in PMR treatment

CHMP recommends marketing authorization for Cosentyx in polymyalgia rheumatica. Drug becomes first IL-17A inhibitor approved in Europe for PMR if finalized. REPLENISH trial showed doubled sustained remission rates versus placebo. Treatment offers steroid-sparing benefits with consistent safety profile. European Commission decision expected within two months of CHMP opinion.